Source comparison
Tesamorelin Visceral Fat Reduction Complete Guide 2026: [Type] Comparison
How does tesamorelin compare to other VAT-reduction strategies in 2026? This table breaks down mechanism, timeline, selectivity, and clinical evidence. Tesamorelin 2mg/day GHRH receptor agonist → pulsatile GH release → hormone-sensitive lipase activation in vi
This comparison does not assign a generated winner or score.
- How does tesamorelin compare to other VAT-reduction strategies in 2026? This table breaks down mechanism, timeline, selectivity, and clinical evidence.
- Tesamorelin 2mg/day
- GHRH receptor agonist → pulsatile GH release → hormone-sensitive lipase activation in visceral adipocytes
- 15–20% (CT/MRI-confirmed)
- Minimal to none
- HOMA-IR ↓ 30–40%, triglycerides ↓ 12–18%, liver fat ↓ 22%
- Most selective for VAT; no appetite suppression required; best for patients with isolated visceral adiposity and normal BMI
- Semaglutide 2.4mg/week
- GLP-1 receptor agonist → delayed gastric emptying + central appetite suppression
- 8–12% (indirect via total weight loss)
- Significant (proportional to total fat loss)
- A1C ↓ 1.5–2.0%, fasting glucose ↓ 15–25 mg/dL
- Non-selective fat loss; VAT reduction tied to overall caloric deficit; superior for patients needing total body weight reduction
- Caloric Restriction (500 kcal/day deficit)
- Energy deficit → adipose lipolysis driven by cortisol and catecholamines
- 5–8% (highly variable)
- Significant (often more than VAT)
- Variable; metabolic adaptation often blunts improvements after 12–16 weeks
- Least selective; compliance-dependent; VAT-to-subcutaneous ratio often unfavourable compared to pharmacologic intervention
- Resistance Training (4x/week)
- Myokine secretion + insulin sensitivity improvements → modest preferential VAT mobilisation
- 3–6% (requires 6+ months)
- Minimal fat loss; lean mass gain
- HOMA-IR ↓ 10–15%, fasting insulin ↓ 8–12%
- Slowest timeline; best as adjunct to pharmacologic therapy; muscle gain can offset scale weight despite fat loss